Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed presents CEO survey to FDA. Former ArthoCare exec pleads guilty to securities fraud charges from DOJ. CMS lists teaching hospitals that qualify for inclusion in company’s physician payment sunshine disclosure requirements. More news.

You may also be interested in...



Ex-ArthroCare Chiefs Convicted Of Orchestrating Fraud

The former top leaders of ArthroCare have been convicted for working in cahoots with distributors to overstate ArthroCare’s earnings. Both face significant prison time for their roles in the scam, according to the Department of Justice.

News Briefs: FDA Turns Down Wright’s Augment; Cook Resumes Zilver PTX Shipments; Luminex Restructures

Wright Medical receives not approvable letter for its Augment bone graft asking for another study. Judge rules against Zimmer in favor of Strkyer in patent case. Cook Medical has resolved the problems that triggered a December 2012 recall of its Zilver PTX peripheral stent. Luminex cuts staff, invests in molecular diagnostics efforts.

News Briefs: User Fee Bill, Sunshine Mobile Apps, More

The House introduced a bill that would exempt device and drug user fees from sequestration cuts. CMS releases two mobile apps to help track payments required under the Sunshine law. More news.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel